Meridian Bioscience Provides an Update on the Revogene® SARS-CoV-2 EUA Submission
CINCINNATI, Feb. 16, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, provided an update on its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene® platform. In its ongoing discussion […]